Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 819-824

John Wiley & Sons Inc

Access to resources Recommend Favorite

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 282-287

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid reduction in BCR‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 27-35

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

By Michallet Mauricette   Tulliez Michel   Corm Sélim   Gardembas Martine   Huguet Françoise   Oukessou Abderrahim   Bregman Bruno   Vekhoff Anne   Ghomari Kamel   Cambier Nathalie   Guerci-Bresler Agnès  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 307-317

Informa Healthcare

Access to resources Recommend Favorite